217691

CDC25 Phosphatase Inhibitor I, BN82002

The CDC25 Phosphatase Inhibitor I, BN82002, also referenced under CAS 396073-89-5, controls the biological activity of CDC25 Phosphatase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications.

• Synonym(s): CDC25 Phosphatase Inhibitor I, BN82002, N-(2-Hydroxy-3-methoxy-5-dimethylamino)benzyl, Nʹ-(2-(4-nitrophenethyl)), Nʹʹ-methylamine, PTP Inhibitor XX
• Empirical Formula (Hill Notation): C₁₉H₂₅N₃O₄
• CAS Number: 396073-89-5
• Molecular Weight: 359.42
• UNSPSC Code: 12352200

Properties

• Quality Level: 100
• Assay: ≥95% (HPLC)
• form: solid
• manufacturer/tradename: Calbiochem^®
• storage condition: OK to freeze; protect from light
• color: red to dark red
• solubility: DMSO: 10 mg/mL; ethanol: 10 mg/mL
• shipped in: ambient
• storage temp.: −20°C
• InChI: 1S/C19H25N3O4/c1-20(2)17-11-15(19(23)18(12-17)26-4)13-21(3)10-9-14-5-7-16(8-6-14)22(24)25/h5-8,11-12,23H,9-10,13H2,1-4H3
• InChI key: GOKYHQGRIIXMNE-UHFFFAOYSA-N

Description

General description

A cell-permeable ortho-hydroxybenzylamino compound that displays anti-tumor properties. Acts as a potent, selective, and irreversible inhibitor of CDC25 phosphatase family (IC₅₀ = 2.4, 3.9, 6.3, 5.4, and 4.6 µM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). Displays ~20-fold greater selectivity for CDC25 phosphatases compared to CD45 tyrosine phosphatase. Shown to delay cell cycle progression in vitro (IC₅₀ in the range of 7.2-32.6 µM), and reduces tumor growth in athymic mice xenografted with the human pancreatic cell MIA PaCa-2 (15 mg/kg, i.p. route).

A cell-permeable ortho-hydroxybenzylamino compound that displays antitumor properties. Acts as a potent, selective and irreversible inhibitor of CDC25 phosphatase family (IC₅₀ = 2.4, 3.9, 6.3, 5.4, and 4.6 µM for 25A, 25B2, 25B3, 25C, and 25C-cat, respectively). Displays ~20-fold greater selectivity for CDC25 phosphatases over CD45 tyrosine phosphatase. Shown to delay cell cycle progression in vitro (IC₅₀ = ~7.2-32.6 µM), and reduces tumor growth in athymic mice xenografted with the human pancreatic cells MIA PaCa-2 (15 mg/kg, i.p. route).

Biochem/physiol Actions

Cell permeable: yes

Primary Target
CDC25A

Product does not compete with ATP.

Reversible: no

Target IC₅₀: 2.4, 3.9, 6.3, 5.4, and 4.6 µM for CDC25 phosphatase family 25A, 25B2, 25B3, 25C, and 25C-cat, respectively

Packaging

Packaged under inert gas

Warning

Toxicity: Standard Handling (A)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Unstable in aqueous solution.

Other Notes

Brezak, M.C., et al. 2004. Cancer Res.64, 3320.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Safety Information

• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 1
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable